Surface Oncology Inc SURF:NASDAQ

Last Price$1.76NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/24/22

Today's Change-0.03(1.68%)
Bid (Size)$1.67 (1)
Ask (Size)$1.99 (5)
Day Low / High$1.67 - 1.85
Volume4.8 M

Surface Oncology Starts Two Mid-Stage Trials of Experimental Cancer Drug

8:13AM ET 4/14/2022 MT Newswires
Surface Oncology (SURF) said Thursday it has started two mid-stage trials on its experimental cancer drug SRF388 as a standalone therapy and as a part of a combination treatment.

The first phase 2 study will enroll about 100 liver cancer patients who had no prior treatment, the company said. It will test the ability of SRF388 in improving progression-free survival when combined with Roche's atezolizumab and bevacizumab. Final data are expected in the first half of 2024.

The second phase 2 trial is enrolling up to 40 non-small-cell lung cancer patients who had at least one round of treatment to test SRF388 as a standalone therapy. The primary endpoint will be overall response rate, with data readout expected next year.

The drugmaker's shares were up 4.6% in recent early premarket activity Thursday.

Price: 2.75, Change: +0.12, Percent Change: +4.56